Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
22 Agosto 2023 - 8:25AM
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the
Company”), a biotechnology company dedicated to developing disease
modifying treatments for neurodegenerative diseases, today
announced that poster presentations from its bioMUSE natural
history study of Multiple System Atrophy (MSA) will be delivered at
the International Congress of Parkinson’s Disease and Movement
Disorders taking place August 27 - 31, 2023 in Copenhagen, Denmark.
Title: |
A multimodal approach for diagnosis of early Multiple System
Atrophy |
Presenter: |
Daniel
O. Claassen, M.D., M.S., Professor of Neurology, Vanderbilt
University Medical Center |
Abstract
#: |
162 |
Category: |
Parkinsonism, Atypical: MSA |
Date: |
Monday,
August 28, 2023 |
Time: |
13:00 -
15:00 local time |
|
|
Title: |
Preliminary evidence for evolution of myoinositol and
N-acetylaspartate as biomarkers of disease severity in early-stage
Multiple System Atrophy |
Presenter: |
Paula
Trujillo Diaz, PhD, Research Assistant Professor, Department of
Neurology, Vanderbilt University Medical Center |
Abstract
#: |
181 |
Category: |
Parkinsonism, Atypical: MSA |
Date: |
Monday,
August 28, 2023 |
Time: |
13:00 -
15:00 local time |
|
|
About bioMUSE
Biomarkers of progression in Multiple System
Atrophy (bioMUSE) is a natural history study that aims to track the
progression of individuals with MSA, a parkinsonian disorder
without approved therapy. The study is being conducted in
collaboration with Vanderbilt University Medical Center in the U.S.
under the direction of Daniel Claassen, M.D., M.S., Professor of
Neurology and Principal Investigator. Natural history studies are
important for characterizing disease progression in selected
patient populations. The study has provided rich data for
optimizing the design of Alterity’s randomized ATH434-201 Phase 2
clinical trial and enrolled approximately 20 individuals with
clinically probable or clinically established MSA. BioMUSE
continues to provide vital information on early stage MSA patients,
informs the selection of biomarkers suitable to evaluate target
engagement and preliminary efficacy, and delivers clinical data to
characterize disease progression in a patient population that
mirrors those currently enrolling in the Phase 2 clinical
trial.
About Multiple System
Atrophy
Multiple System Atrophy (MSA) is a rare,
neurodegenerative disease characterized by failure of the autonomic
nervous system and impaired movement. The symptoms reflect the
progressive loss of function and death of different types of nerve
cells in the brain and spinal cord. It is a rapidly progressive
disease and causes profound disability. MSA is a Parkinsonian
disorder characterized by a variable combination of slowed movement
and/or rigidity, autonomic instability that affects involuntary
functions such as blood pressure maintenance and bladder control,
and impaired balance and/or coordination that predisposes to falls.
A pathological hallmark of MSA is the accumulation of the protein
α-synuclein within glia, the support cells of the central nervous
system, and neuron loss in multiple brain regions. MSA affects
approximately 15,000 individuals in the U.S., and while some of the
symptoms of MSA can be treated with medications, currently there
are no drugs that are able to slow disease progression and there is
no cure.1
1Multiple System Atrophy | National Institute of Neurological
Disorders and Stroke (nih.gov)
About Alterity Therapeutics
Limited
Alterity Therapeutics is a clinical stage
biotechnology company dedicated to creating an alternate future for
people living with neurodegenerative diseases. The Company’s
lead asset, ATH434, has the potential to treat various Parkinsonian
disorders and is currently being evaluated in two Phase 2 clinical
trials in Multiple System Atrophy. Alterity also has a broad drug
discovery platform generating patentable chemical compounds to
treat the underlying pathology of neurological diseases. The
Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s
web site at www.alteritytherapeutics.com.
Authorisation & Additional informationThis
announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.
Investor and Media Contacts:
AustraliaHannah
Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648
064
U.S.Remy Bernardaremy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of section 27A of the Securities Act
of 1933 and section 21E of the Securities Exchange Act of 1934. The
Company has tried to identify such forward-looking statements by
use of such words as "expects," "intends," "hopes," "anticipates,"
"believes," "could," "may," "evidences" and "estimates," and other
similar expressions, but these words are not the exclusive means of
identifying such statements.
Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements are described in the sections titled
“Risk Factors” in the Company’s filings with the SEC, including its
most recent Annual Report on Form 20-F as well as reports on Form
6-K, including, but not limited to the following: statements
relating to the Company's drug development program, including, but
not limited to the initiation, progress and outcomes of clinical
trials of the Company's drug development program, including, but
not limited to, ATH434, and any other statements that are not
historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties
relating to the difficulties or delays in financing, development,
testing, regulatory approval, production and marketing of the
Company’s drug components, including, but not limited to, ATH434,
the ability of the Company to procure additional future sources of
financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company's drug compounds, including,
but not limited to, ATH434, that could slow or prevent products
coming to market, the uncertainty of obtaining patent protection
for the Company's intellectual property or trade secrets, the
uncertainty of successfully enforcing the Company’s patent rights
and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this
press release is based only on information currently available to
us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
Alterity Therapeutics (NASDAQ:ATHE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Alterity Therapeutics (NASDAQ:ATHE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024